Mechanisms of Resistance to Androgen Deprivation Therapy in Advanced Castration Resistant Prostate Cancer (CRPC)

reportActive / Technical Report | Accesssion Number: AD1116935 | Open PDF

Abstract:

The overall hypothesis is that expression of the dipeptidase DPP4 is downregulated in prostate cancer (PCa) as a mechanism of resistance to androgen deprivation therapy (ADT). My overall objective is to demonstrate that DPP4 downregulation is a mechanism of ADT-resistance and PCa progression and to identify the specific pro-survival growth factor/cytokine targeted by DPP4 for degradation and its associated signaling cascade. Aim 1 will assess the effect ofDPP4 downregulation and overexpression on the sensitivity of PCa xenografts to castration. Aim 2 will identify the pro-survival growth factor/cytokine targeted by DPP4 for degradation and the downstream signaling cascades effected. Aim 3 will extend the significance of DPP4downregulation into primary PCa and CRPC clinical specimens and assess the interaction ofDPP4 inhibition with ADT.

Author(s):
Russo, Joshua W.
Author Organization(s):
Beth Israel Deaconess Medical Center
Funding Organization(s):
Publication Date:
2020 Oct 01
Pagination:
0

Security Markings

RECORD

Collection: TRECMS
Subject Terms
Communities of Interest:
Biomedical
Descriptor(s):
biomedical research, health services, medical personnel, governments, prostate cancer, cell line, growth factors, lymphocytes, neoplasms, cells, chemistry, cytokines, humanities, professional development, proteins, state governments, androgen receptors
Keyword(s):
DPP4, CD26, castration-resistance, androgen deprivation therapy, growth factor
Subject Categories:
Biological and Medical Sciences
Update Date:
2020 Dec 09